熱門資訊> 正文
Bria-IMG第二阶段数据积极，BriaCell股价飙升150%
2024-09-11 22:36
- Shares of BriaCell Therapeutics (NASDAQ:BCTX) soared 150% in morning trading Wednesday after the company reported positive overall survival data from a Phase 2 study for its therapy Bria-IMT in the treatment of metastatic breast cancer.
- The study showed a medial overall survival of 15.6 months for patients treated with Bri-IMT in combination with an immune checkpoint inhibitor, compared with 6.7 to 9.3 months for similar patients reported in the literature, according to a statement.
- The patients were administered the same formulation of the product that is being used in an ongoing Phase 3 pivotal study for the product, BriaCell added.
More on Briacell Therapeutics
- Seeking Alpha’s Quant Rating on Briacell Therapeutics
- Historical earnings data for Briacell Therapeutics
- Financial information for Briacell Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
